Sort
82,697 grants matching “vaccine development”
Pathobiology and treatment of patients with severe combined immunodeficiency
$1,099,982Sung-Yun Pai · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Assembly and export of mycobacterial lipoglycans
$1,099,930Mary Jackson · Colorado State University · R01 · FY2025 · AI
DEVELOPMENT OF A LIVE ATTENUATED POWASSAN VIRUS VACCINE
$1,099,897Rockefeller University · · FY2019 · Defense Health Agency
Vector Biological Studies in Leishmaniasis
$1,099,773David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Ontogeny &Maintenance of Virus Specific T Cells
$1,099,679Univ Of Massachusetts Med Sch Worcester · P01 · FY2005 · AI
Biochemical and structural mechanisms at the filoviral-host interface
$1,099,141Gaya K. Amarasinghe · Washington University · P01 · FY2025 · AI
RP3: Therapeutics Human Monoclonal Antibody Treatments for Filoviruses
$1,099,053James E Crowe · University Of Texas Med Br Galveston · U19 · FY2016 · AI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,098,964John Givens · Starks Associates Inc · N01 · FY2016 · AI
MOLECULAR THERAPEUTICS OF RHEUMATOID ARTHRITIS
$1,098,930University Of California San Diego · P50 · FY2001 · AR
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,098,906Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
CAP-IT Center for LNP RNA Immunoprevention
$1,098,880Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2023 · CA
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$1,098,673Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Advanced Development of a Combined Shigella-ETEC Vaccine
$1,098,552Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2025 · AI
Oklahoma Center for Respiratory and Infectious Diseases
$1,098,507Lin Liu · Oklahoma State University Stillwater · P30 · FY2025 · GM
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
$1,098,437Xiangpeng Kong · New York University School Of Medicine · R01 · FY2022 · AI
Development Of New Approaches To Vaccines Against TBEV and West Nile Virus
$1,098,362Alexander Pletnev · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS
$1,098,305Mount Sinai School Of Medicine Of Nyu · P01 · FY2003 · AI
Phase II Trial of H7N9 Influenza Vaccines - VTEU
$1,098,151Karen L. Kotloff · University Of Maryland Baltimore · N01 · FY2014 · AI
Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine
$1,097,998Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
$1,097,964Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Harvard Medical School Vaccine Clinical Trials Unit
$1,097,943Raphael Dolin · Beth Israel Deaconess Medical Center · U01 · FY2009 · AI
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment
$1,097,704Chang-Guo Zhan · University Of Kentucky · R01 · FY2014 · DA
Signal Transduction Events and the Regulation of Cell Growth
$1,097,545Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2020 · CA
Development of a Safe and Effective Vaccine Against West Nile Virus
$1,097,443Mark K Slifka · Oregon Health & Science University · U01 · FY2012 · AI
Development of a post-exposure vaccine for smallpox
$1,097,389Arizona State University-Tempe Campus · R01 · FY2005 · AI